Eli Lilly and Company

LLY

US5324571083

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Employees

43,000

Sector

Pharmaceuticals

Calendar

30/10/2024 - Q3 2024 Earnings Release

More about the company

Income Statement and Estimates

More financial data

Analysis / Opinion

David Ricks, CEO of Eli Lilly: A market of over a billion people

March 12, 2024 at 06:47 pm

More Strategies

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

923.71USD

Average target price

995.42USD

Spread / Average Target

+7.76%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Nyse Other stock markets 21:00:02 13/09/2024 BST			5-day change	1st Jan Change
923.71 ^USD	-1.21%		+2.33%	+58.46%

09-13	Eli Lilly Gets FDA Approval for Eczema Treatment Ebglyss	DJ
09-13	Eli Lilly Gets US FDA Approval for Atopic Dermatitis Treatment	MT

Eli Lilly Gets FDA Approval for Eczema Treatment Ebglyss	09-13	DJ
Eli Lilly Gets US FDA Approval for Atopic Dermatitis Treatment	09-13	MT
FDA Approves Lilly's EBGLYSS (Lebrikizumab-Lbkz) for Adults and Children 12 Years and Older with Moderate-To-Severe Atopic Dermatitis	09-13	CI
Correction to Eli Lilly Gets FDA Approval for Eczema Treatment Article	09-13	DJ
A central bank and it's off again?	09-13
JPMorgan Raises Price Target on Eli Lilly to $1,100 From $1,050	09-13	MT
Eli Lilly to Expand Two Ireland Sites With $1.8 Billion Investment	09-13	MT
Eli Lilly invests $1.8 billion in Ireland sites to scale up Alzheimer's, obesity drug production	09-13	RE
Sector Update: Health Care Stocks Rise in Thursday Trading	09-12	MT
Sector Update: Health Care	09-12	MT
Top Midday Stories: Moderna Shares Tumble on R&D Expense Cuts; Mastercard to Buy Recorded Future for $2.65 Billion	09-12	MT
Eli Lilly Investing Additional $1 Billion in Ireland Manufacturing Plant	09-12	DJ
ECB to cut rates without lowering its guard	09-12
Eli Lilly: invests $1.8 billion in two sites in Ireland	09-12	CF
Eli Lilly Invests $1.8 Billion in Ireland Site Expansions	09-12	MT
Roche shares drop on side effects result in early-stage obesity pill trial	09-12	RE
Eli Lilly: phase 3 trials on weekly insulin	09-11	CF
Health Care Up on Defensive Bias -- Health Care Roundup	09-10	DJ
Weight-loss market to see 16 new drugs by 2029, report estimates	09-10	RE
Eli Lilly Says Efsitora Effective in Adults With Type 1 or 2 Diabetes in Phase 3 Trials	09-10	MT
Nanosyrinx Ltd. announced that it has received £10 million in funding from BGF Investment Management Ltd., Merck Ventures B.V., Octopus Ventures Ltd., Eli Lilly and Company, IQ Capital Partners LLP, Meltwind Advisory	09-09	CI
Lilly appoints insider as finance chief amid rising investments to boost capacity	09-09	RE
The market burns its idols	09-09
Eli Lilly Appoints New Finance Chief	09-09	MT
Eli Lilly: in-house executive appointed CFO	09-09	CF

Eli Lilly and Company

Equities

LLY